Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775284 | 0.90 | HRH4 (0.46) | HRH4HRH3HRH2CHRM1CHRM2 | |
| SCHEMBL30775327 | 0.85 | CHRM1 (0.39) | HRH4HRH3HRH2CHRM1CHRNB2 | |
| SCHEMBL30775263 | 0.80 | HTR7 (0.44) | HRH4HRH3HRH2 | |
| SCHEMBL30775218 | 0.76 | CHRNB2 (0.41) | CHRM1CACNA2D1CHRNB2CHRNA4PRKCZ | |
| SCHEMBL30775298 | 0.75 | CHRM1 (0.43) | CHRM1PIK3CDCHRNB2CHRNA4PRKCZ | |
| SCHEMBL30775307 | 0.74 | CHRM1 (0.41) | CHRM1CHRNB2CHRNA4PRKCZ | |
| SCHEMBL30775276 | 0.73 | SYK (0.47) | HRH4HRH3CHRM1CACNA2D1CHRM2 | |
| SCHEMBL30775197 | 0.73 | CHRM1 (0.44) | CHRM1PIK3CDCHRNB2CHRNA4PRKCZ | |
| SCHEMBL30775301 | 0.72 | ELOVL1 (0.42) | CHRNB2CHRNA4PRKCZ | |
| SCHEMBL30775260 | 0.71 | ELOVL1 (0.43) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | HRH4 3323/4885HRH3 3202/4885HRH2 968/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HRH4 3323/4885HRH3 3202/4885HRH2 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.